Ketamine inhibits endometrial cancer cell growth and motility by inducing ferroptosis.

Endometrial cancer (EC) is a prevalent gynecological malignancy with an escalating incidence and mortality rate, notably in China. Surgical options are limited, and drug resistance development poses significant challenges to EC treatment. Ketamine, a rapidacting anesthetic, exhibits anti-inflammatory, analgesic, and antidepressant properties, yet its potential in cancer therapy remains largely unexplored. Here, we investigate ketamine’s effects on EC cell growth, motility and ferroptosis, alongside its impact on the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/the mammalian target of rapamycin (mTOR) axis. Ketamine significantly inhibits EC cell growth and motility while promoting ferroptosis. Mechanistically, ketamine’s anti-tumor effects correlate with suppression of the PI3K/Akt/mTOR axis crucial for cell survival and growth. In summary, our findings highlight ketamine’s potential therapeutic application in EC treatment by impeding cell growth and motility, fostering ferroptosis, and suppressing the PI3K/Akt/mTOR axis. These insights offer novel avenues for EC therapy. [ABSTRACT FROM AUTHOR]